BACKGROUND Pulmonary hypertension and associated right ventricular (RV) dysfunction are important determinants
, which provides further motivation to apply a more global metabolite profiling approach to PH. Ultimately, metabolite profiling might highlight measures to redress metabolic derangements in RV-PV dysfunction (6, 7) .
In this study, we hypothesized that simultaneous invasive hemodynamic measurements during rightsided heart catheterization and blood sampling in dyspneic subjects would permit derivation of metabolic signatures of RV-PV dysfunction. We recruited subjects with dyspnea and a wide range of right-sided heart catheterization hemodynamic profiles, as well as predefined groups of people with and without known World Health Organization Group 1 pulmonary arterial hypertension (PAH), to identify metabolite profiles of RV-PV dysfunction. We performed blood sampling in multiple anatomic sites to localize the source of metabolic signatures. To optimize the precision of our phenotyping of RV-PV dysfunction, we also measured the degree of impairment in exercise capacity (peak oxygen uptake [VO 2 ]) and performed minute-by-minute hemodynamic measurements across varying RV loading conditions during exercise to probe the capacity of the RV-PV unit to accommodate increased blood flow (8) .
Furthermore, we used a well-described animal model to evaluate the expression of key enzymes and metabolites in an emerging pathway associated with PH in our human studies. with first-pass radionuclide ventriculography was performed as described previously (7,10) (Online Appendix, Online Figure 1 ). In the third PAH versus control validation cohort, peripheral venous plasma samples were obtained in the fasting state at 3 (median interquartile range: 0 to 6) days from the time of right-sided heart catheterization documenting PAH.
METHODS
Profiles of plasma metabolites were obtained by use of a multiplexed liquid chromatography mass spectrometry (LC-MS) system as described previously Table 2 ). The ratio of arginine to ornithine þ citrulline, which reflects global arginine bioavailability and has emerged as a potential PH biomarker in select PH populations with sickle cell disease (13) and heart failure (1), was inversely related to PAP, PVR, and DPQ (all p < 0.005) ( Table 2) . A cluster of purine degradation products (i.e., purine-Ms: allantoin, xanthosine, inosine, xanthine, uric acid) was also closely related to RV-PV dysfunction. Several of these purine-Ms are associated with oxidative stress, although only urate has been associated with PH (14) .
The amino acid tryptophan can be metabolized via 2 enzymatic pathways: tryptophan hydroxylase (TH), which yields serotonin (5-hydroxytryptophan) and the main metabolite of serotonin (5-hydroxyindoleacetic acid), or via IDO, which generates kynurenine, anthranilate, kynurenate, and quinolinate.
We identified striking associations between RV-PV dysfunction and IDO-TMs ( Figure 1 , Table 2 ) that have Although many of the metabolites highlighted by the LC-MS based platform fell into previously described pathways, other metabolites had less obvious metabolic connections ( Figure 1) . We identified associations between indexes of RV-PV dysfunction and the catecholamine vanillylmandelic acid, as well as aminoisobutyric acid and cyclic adenosine monophosphate, 2 additional metabolites potentially related to sympathetic nervous system activation (16, 17) .
Plasma levels of the homocysteine metabolite cystathionine, as well as glyceraldehyde and glucoronate,
were also related to indexes of RV-PV dysfunction.
MULTIMARKER SCORES. To assess how clusters of metabolites from a given metabolic pathway relate to hemodynamic measurements, composite scores were generated by summing z-scores of individual metabolites weighted by b-coefficients within clusters (18) ( Table 2) . Composite scores from each group, adjusted for age and sex, were closely related to PAP and PVR at rest ( Table 2) . Table 2 ).
The novel finding in humans that IDO-dependent (Table 5) .
To further assess the performance of IDO-TMs as potential markers of RV-PV dysfunction, we also examined IDO-TM levels in an independent cohort of patients with known World Health Organization Group 1 PAH and control subjects of similar age, sex, and BMI ( Table 6 Furthermore, we identified circulating metabolites Table 2 ). These findings extend previous work demonstrating that Arg/(OrnþCit) ratio is a marker of PH severity in select PH-populations with sickle cell disease (13) and LV systolic dysfunction Ours is the first study to relate circulating levels of succinate and other TCA cycle intermediates to PH, which raises the possibility that succinate or potentially other TCA-related metabolites could modulate vascular tone in humans.
There is mounting evidence of abnormal mitochondrial function, both within and outside the pulmonary circulation in PH. Beyond a wellrecognized glycolytic shift that occurs in PH (37), down-regulation of the mitochondrial deacetylase sirtuin 3 has also been implicated in mitochondrial dysfunction in PH (38) . The extent to which circulating TCA cycle or glycolytic intermediates accurately reflect mitochondrial dysfunction in PH will be an important area of future investigation.
We also found that metabolites that may relate to sympathetic nervous system activation tracked with RV-PV dysfunction (i.e., vanillylmandelic acid, cyclic adenosine monophosphate, and aminoisobutyric acid). These findings are consistent with previous studies relating heightened catecholamine levels to pulmonary vasoconstriction (17) .
STUDY LIMITATIONS. We used a liquid chromatography tandem mass spectrometry platform that provides key "sentinels" across known metabolic pathways but does not fully cover the entire plasma metabolome. Our study design focused on subjects with dyspnea on exertion in the main derivation and validation cohorts, as opposed to a narrowly defined patient population with PH, which resulted in heterogeneity in pathogenesis and degree of PH in our cohort. However, because PH purports a poor Abbreviations as in Table 2 . metabolites that are known to be increased in the setting of uremia (39) . We excluded patients with advanced kidney disease, and average creatinine levels were normal in both our derivation and validation cohorts (1.1 mg/dl in each). Furthermore, we adjusted for cystatin C concentrations and found that IDO-TM, but not other TMs such as indoxysulfate, remained strongly predictive of pulmonary hemodynamic measurements. Simultaneous peripheral venous and central venous sampling was not available to permit comparison of metabolite levels from the 2 sampling sites. The small sample size of the validation cohort limited our power to identify additional metabolites that may have differed between PAH and control subjects. Finally, in our animal model studies, we acknowledge that the cellular source of metabolites within the lung was not localized, and we did not include invasive hemodynamic measurements to document the degree of PH elicited by hypoxia. However, Fulton ratios were similar to those in other studies in which a >2-fold increment in PAP was obtained (33) . 
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